Expertise in
5
conditions

Dr. Robert Findling

Child and Adolescent Psychiatry
Virginia Treatment Center For Children (Vtcc)-Inpatient
1308 Sherwood Ave, 
Richmond, VA 
Offers Telehealth
Expertise in
5
conditions
Virginia Treatment Center For Children (Vtcc)-Inpatient
1308 Sherwood Ave, 
Richmond, VA 

Overview

Robert Findling is a Child and Adolescent Psychiatrist in Richmond, Virginia. Dr. Findling is highly rated in 5 conditions, according to our data. His top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (BPD), Autism Spectrum Disorder, and Schizophrenia.

His clinical research consists of co-authoring 280 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Child and Adolescent Psychiatry

Licenses

Child & Adolescent Psychiatry in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
View 2 Less Insurance Carriers -

Locations

Virginia Treatment Center For Children (Vtcc)-Inpatient
1308 Sherwood Ave, Richmond, VA 23220

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
Enrollment Status: Terminated
Publish Date: May 09, 2024
Intervention Type: Drug
Study Drug: NaBen®
Study Phase: Phase 2/Phase 3
A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder
A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder
Enrollment Status: Terminated
Publish Date: March 03, 2023
Intervention Type: Drug
Study Drug: Carbamazepine
Study Phase: Phase 4
A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: March 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: August 14, 2020
Intervention Type: Device
Study Phase: Not Applicable
A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects
A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects
Enrollment Status: Completed
Publish Date: December 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

280 Total Publications

Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial.
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial.
Journal: CNS drugs
Published: July 10, 2025
Similar Doctors
Expertise in
10
conditions
Dr. Thresa H. Simon
Child and Adolescent Psychiatry | Psychiatry
Expertise in
10
conditions
Dr. Thresa H. Simon
Child and Adolescent Psychiatry | Psychiatry

Virginia South Psychiatric And Family Services

269 Medical Park Blvd, 
Petersburg, VA 
 (374.6 miles away)
804-861-0700
Languages Spoken:
English, Spanish, Tamil, Telugu, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Thresa Simon is a Child and Adolescent Psychiatrist and a Psychiatrist in Petersburg, Virginia. Dr. Simon is highly rated in 10 conditions, according to our data. Her top areas of expertise are Schizoaffective Disorder, Bipolar Disorder (BPD), Seasonal Affective Disorder (SAD), and Schizophrenia. Dr. Simon is currently accepting new patients.

Expertise in
9
conditions
Dr. Salman Siddiqui
Child and Adolescent Psychiatry | Psychiatry
Expertise in
9
conditions
Dr. Salman Siddiqui
Child and Adolescent Psychiatry | Psychiatry

Virginia South Psychiatric And Family Services

207 N 4th Ave, 
Hopewell, VA 
 (370.7 miles away)
804-518-6513
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Salman Siddiqui is a Child and Adolescent Psychiatrist and a Psychiatrist in Hopewell, Virginia. Dr. Siddiqui is highly rated in 9 conditions, according to our data. His top areas of expertise are Schizoaffective Disorder, Major Depression, Seasonal Affective Disorder (SAD), and Schizophrenia. Dr. Siddiqui is currently accepting new patients.

Expertise in
8
conditions
Dr. Rakesh K. Shah
Child and Adolescent Psychiatry | Psychiatry
Expertise in
8
conditions
Dr. Rakesh K. Shah
Child and Adolescent Psychiatry | Psychiatry

Virginia South Psychiatric And Family Services

207 N 4th Ave, 
Hopewell, VA 
 (370.7 miles away)
804-518-6513
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rakesh Shah is a Child and Adolescent Psychiatrist and a Psychiatrist in Hopewell, Virginia. Dr. Shah is highly rated in 8 conditions, according to our data. His top areas of expertise are Schizoaffective Disorder, Seasonal Affective Disorder (SAD), Major Depression, and Bipolar Disorder (BPD). Dr. Shah is currently accepting new patients.

Frequently Asked Questions about Dr. Robert Findling

How do I make an appointment with Dr. Robert Findling?

You can book an appointment with Dr. Robert Findling by calling their office at 804-828-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert Findling a top-rated expert for Attention Deficit Hyperactivity Disorder (ADHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert Findling is classified as an Elite expert for Attention Deficit Hyperactivity Disorder (ADHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert Findling specialize in?

While Dr. Robert Findling is a Child and Adolescent Psychiatry, they have specific expertise in Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (BPD), and Autism Spectrum Disorder. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Child and Adolescent Psychiatry.

Does Dr. Robert Findling participate in research or clinical trials?

Yes. Dr. Robert Findling has published 280 articles and abstracts on conditions like Attention Deficit Hyperactivity Disorder (ADHD). You can view a list of Dr. Robert Findling's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert Findling accept my insurance?

Dr. Robert Findling accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 804-828-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Findling's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile